Quebec Reveals Details Of Biosimilar Switching Policy
Biosimilars Canada Welcomes Initiative As Other Provinces Pursue Similar Schemes
Quebec has revealed further details of its biosimilar switching policy which is expected to generate annual savings of CAD100m by 2022. The move has received support from Biosimilars Canada, as other Canadian provinces pursue similar initiatives.
You may also be interested in...
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.
Canadian firm Valeo Pharma revealed the extent of coverage for its Lovenox biosimilars, months after launching the low molecular weight heparin in-licensed from Shenzhen Techdow Pharmaceutical.
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.